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To the Editor:
With the advent of small molecule inhibitors, sustained
responses in chronic lymphocytic leukemia (CLL) patients
have been achieved. Ibrutinib, an inhibitor of Bruton’s tyr-
osine kinase (BTK), is a particularly potent treatment for
CLL, with overall response rates of 82% in treatment-naive
and 43% in relapsed-refractory patients [1]. These responses
are accompanied by transient lymphocytosis in 50–70% of
patients and a concomitant reduction of tumor burden in
lymphoid organs [2]. We have recently demonstrated that the
high-risk, CD49d-high CLL subgroup [3] displays reduced
lymphocytosis and minor lymph node shrinkage upon ibru-
tinib treatment [4]. CD49d is the alpha subunit of the integrin
VLA-4, which plays an essential role in the tissue retention
of cells, orchestrating their adhesion to stromal cells, e.g.,
follicular dendritic cells (fDCs), which in turn express the
VLA-4 ligand VCAM-1. To facilitate this strong adhesion,
VLA-4 needs to be activated [5]. We have demonstrated that
in CLL the extended, high-affinity conformation of VLA-4
can be triggered by B cell receptor (BCR) stimulation [4].
Notably, upon treatment with ibrutinib, CD49d-high CLL
cells maintain residual BCR-mediated inside-out activation
of VLA-4, thus explaining the reduced clinical response of
CD49d-expressing CLL [4].
Eµ-TCL1-transgenic (TCL1-tg) mice represent a widely
used mouse model for CLL [6]. By using this model, here
we found that: (i) murine leukemic cells express high levels
of surface CD49d; (ii) the BCR-VLA-4 axis in TCL1-tg
mice, as investigated upon BCR stimulation and/or expo-
sure to BCR inhibitors, resembles that of the human
CD49d-high CLL cohort; (iii) the in vivo distribution of
TCL1-tg leukemic cells is dependent on VLA-4-mediated
interactions with the microenvironment. Our data demon-
strate the value of TCL1-tg mice as a model for CD49d-
high CLL and corroborate the importance of retained BCR-
induced VLA-4 activation in a clinical setting.
First, to compare VLA-4 expression patterns between
human CLL cells and TCL1-tg cells, we measured CD49d
expression of human or murine healthy B cells and leukemic
cells by flow cytometry (antibodies: see Supplementary
Table 1). Human blood samples (N= 406; Supplementary
Table 2) were obtained upon written informed consent and
ethical approval. Blood-derived B cells from age-matched
healthy individuals (N= 32) and CD49d-high CLL cells
(N= 116) expressed similar levels of CD49d (Fig. 1ai).
Previous reports have shown that CD49d-high CLL cells
express lower CD49d levels than healthy B cells. However,
our healthy donor group consisted of strictly age-matched
individuals (average of healthy cohort: 65.8; CLL cohort:
69.63 years), indicating that CD49d expression might be
reduced by age in humans. Moreover, CD49d expression of
blood-derived B cells from age-matched C57BL/6J wild-type
(WT) mice was similar to that of leukemic cells from TCL1-
tg mice (Fig. 1aii). To investigate whether the expression of
These authors contributed equally: Eva Szenes, Andrea Härzschel
* Tanja Nicole Hartmann
tanjanhartmann@gmail.com
1 Department of Internal Medicine III with Hematology, Medical
Oncology, Hemostaseology, Infectiology and Rheumatology,
Oncologic Center, Salzburg Cancer Research Institute—
Laboratory for Immunological and Molecular Cancer Research
(SCRI-LIMCR), Paracelsus Medical University, Salzburg, Austria
2 Department of Internal Medicine I, Medical Center and Faculty of
Medicine, University of Freiburg, Freiburg, Germany
3 Clinical and Experimental Onco-Hematology Unit, Centro di
Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy
4 Department of Pathology and Cancer Center, University of New
Mexico, Albuquerque, NM, USA
Supplementary information The online version of this article (https://
doi.org/10.1038/s41375-020-0759-3) contains supplementary















the VLA-4 subunits (CD49d and CD29) had an organ-
specific pattern, we measured B cells and leukemic cells of
spleen (SPL), bone marrow (BM), lymph nodes (LN), blood
(BL), liver (LIV), and the peritoneal cavity (PC) from WT
and TCL1-tg mice. Remarkably, expression levels of both
integrin subunits were similar in all organs. CD49d mean
fluorescence intensity ratio (MFIR) was comparable in
WT and TCL1-tg mice (mean MFIR of WT= 9.893;
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TCL1-tg= 9.710) (Supplementary Fig. 1a), while the
expression of the CD49d-coupled beta subunit CD29 (beta1)
was higher in TCL1-tg mice (mean MFIR of WT= 7.261;
TCL1-tg= 21.920) (Supplementary Fig. 1b). Altogether, our
data demonstrate that the TCL1-tg model can be used as a
murine surrogate for the CD49d-high CLL cohort, with
stable expression. As expression levels in the spleen and
blood were comparable, and their cellular compositions are
highly similar, we used murine splenocytes in subsequent
experiments.
To relate the CD49d expression pattern to function, we
investigated the mechanistic basis of VLA-4 activation by
BCR stimuli. In human CLL, BCR-induced VLA-4 acti-
vation can be detected by the conformation-sensitive
anti–human CD29 antibody HUTS-21 [4, 7], which does
not recognize the murine epitope. Therefore, here we used
the small molecule VLA-4 ligand LDV [8] and measured its
binding to leukemic cells by flow cytometry as outlined in
Supplementary Fig. 2. With this experimental layout, we
obtained real-time information about the kinetics of VLA-4
affinity regulation resulting in enhanced ligand binding. The
speed by which unlabeled LDV replaces its FITC-
conjugated counterpart (koff) is used to determine integrin
affinity [8]. If VLA-4 and its ligand bind with high
affinity, dissociation of LDV-FITC is slower and the
replacement time is longer, resulting in lower koff values
(below 0.02 s−1). Conversely, low VLA-4-ligand affinity
leads to fast LDV-FITC dissociation, shorter replacement
time, and higher koff values (above 0.06 s
−1). When purified
TCL1-tg leukemic cells were stimulated with anti-mouse-
IgM, VLA-4 affinity increased, with a decrease in koff from
0.055 to 0.04 s−1. This shows for the first time that in
TCL1-tg mice BCR stimulation induces changes in VLA-4
conformation. Ibrutinib pretreatment did not fully prevent
this inside-out activation of VLA-4 (Fig. 1bi), recapitulating
the observations in human CD49d-high CLL cells [4]. Next,
we treated the cells with the phosphoinositide-3-kinase delta
(PI3Kδ) inhibitor idelalisib [9]. Treatment of leukemic cells
with idelalisib (Fig. 1bii) and the ibrutinib/idelalisib com-
bination (Fig. 1biii) was highly effective with no difference
between the affinities of unstimulated compared with sti-
mulated+ idelalisib-treated or stimulated+ combination-
treated cells. In human CLL, neither ibrutinib nor idelalisib
is sufficient on its own to prevent inside-out signaling via
the BCR [4], suggesting that the stimulation can bypass
both BTK and PI3Kδ. In TCL1-tg mice, PI3Kδ seems to be
a dominant molecule that mediates inside-out signaling
between the BCR and VLA-4.
To test that the residual BCR-induced VLA-4 activation
was not a result of insufficient inhibition by ibrutinib, we
measured the phosphorylation of signaling molecules of the
BCR pathway in TCL1-tg splenocytes treated with/without
BCR inhibitors by phosflow. Ibrutinib and idelalisib
showed specific and expected patterns of inhibition. Single-
agent ibrutinib treatment significantly reduced the phos-
phorylation of BTK (Fig. 1ci) and spleen tyrosine kinase
(SYK, Fig. 1cii) after BCR stimulation. Extracellular signal-
regulated kinase 1/2 (ERK1/2, Fig. 1ciii) phospho signal
was decreased by both inhibitors. The phosphorylation of
Akt (Fig. 1civ), the downstream signaling component of
PI3K, was efficiently inhibited by idelalisib. Both inhibitors
showed expected inhibition, therefore, the residual BCR-
mediated VLA-4 activation in ibrutinib-treated cells was not
a result of suboptimal BTK blocking.
Having examined the connection between the BCR and
VLA-4 in vitro, we next investigated the importance of
VLA-4 in engraftment and early disease onset of TCL1-tg-
driven murine leukemia in vivo. Therefore, we transplanted
WT mice with primary TCL1-tg splenocytes [10] and
treated the recipients with vehicle or the small molecule
CD49d-inhibitor firategrast [11]. Recipient mice were
sacrificed and their organs analyzed by flow cytometry
21 days post transplantation. Firategrast-treated mice
showed an overall reduction of leukemic cells in the spleen
(Fig. 2ai), accompanied by significant spleen weight
reduction (Fig. 2aii). Since leukemic cells need to enter the
follicles in the white pulp of the spleen and access fDCs
Fig. 1 TCL1-tg leukemic cells resemble human CD49d-high CLL
cells in their CD49d expression and VLA-4 inside-out signaling. a
The expression of the rate-limiting alpha subunit of VLA-4, CD49d,
was measured by flow cytometry. Samples collected from peripheral
blood of age-matched (Ai) healthy donors (N= 32), CD49d-low (N=
290) or CD49d-high CLL patients (N= 116), and (Aii) C57BL/6 J
wild-type (N= 12) or TCL1-tg mice (N= 12) were stained with anti-
CD5 and anti-CD19, as well as CD49d-specific or its isotype control
antibody. MFIR mean fluorescence intensity ratio (human measure-
ments: arithmetic mean, mouse measurements: geometric mean).
Dotted line: MFIR= 1. Unpaired t tests were performed by GraphPad
Prism5. b Purified murine CD5+/CD19+ cells (N= 5) were treated
for 1 h with/without 1 μM (Bi) ibrutinib (IBR), (Bii) idelalisib (IDEL),
or (Biii) both. The dissociation rate (koff) of VLA-4 and its ligand LDV
was determined by real-time flow cytometry. Koff values are shown
upon different stimulation states: resting (negative control), anti-IgM-
stimulated (F(ab′)2, 10 μg/ml), and pretreated+ anti-IgM-stimulated.
A koff value above 0.06 s
−1 (dotted line) is considered “low affinity”,
while values below 0.02 s−1 (dashed line) are “high affinity.” Con-
necting lines indicate values from the same tumor. Nonlinear fit
“Plateau followed by one-phase decay” and paired t tests were per-
formed using GraphPad Prism5. c Ibrutinib and idelalisib differentially
affect BCR signaling in TCL1-tg mice. Splenocytes from TCL1-tg
mice (N= 6) were pretreated with/without ibrutinib, idealisib or both
(1 μM, 1 h). Cells were stained with anti-CD3 for T cell exclusion and
with fixable viability dye, followed by a stimulation by anti-IgM
(F(ab′)2, 10 μg/ml, 5 min). Cells were fixed and permeabilized, stained
with phosflow antibodies, and measured by flow cytometry. The mean
fluorescence intensity (MFI, geometric mean) values of (Ci) pBTK,
(Cii) pSYK, (Ciii) pERK1/2, and (Civ) pAkt of viable CD3-negative
cells are shown. To validate whether the CD3-negative cell population
corresponds with the leukemic cells, the samples were stained with
anti-CD5 and anti-CD19 in parallel. Connecting lines indicate values
from the same tumor. Paired t tests were performed by GraphPad
Prism5. *P < 0.05; **P < 0.01; ***P < 0.001, ns nonsignificant.
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expressing VCAM-1 and providing proliferative signals
[12], VLA-4 inhibition prevents the cells from staying in
this supportive niche. Indeed, we found a significant
increase of CD5+/CD19+ cells in the blood (Fig. 2aiii)
upon VLA-4 inhibition, without changes in tumor infiltra-
tion in the BM (Fig. 2aiv). This finding was surprising
given the prominent role of VLA-4 in CLL retention in the
BM [13], but at this stage of engraftment the amount of
leukemic cells was still low, and TCL1-tg tumor growth is
driven by the spleen, especially in early stages [14].
To investigate a more advanced disease stage, we repeated
the treatment study using the inhibitory rat-anti-mouse
CD49d antibody PS/2 (Fig. 2b, treatment schedule: see
legend). For long-term treatment, we switched to antibody
therapy because firategrast has a fast turnover in the organ-
ism, although the in vitro inhibitory effects on VLA-4 ligand
binding of the two substances were comparable (confirmed
by adhesion assays, data not shown). The mice were sacri-
ficed 6 weeks post transplantation. Analysis of the organs
revealed decreased tumor burden in the spleen (Fig. 2bi),
along with slightly decreased spleen weight (Fig. 2bii). At
this stage, a significant decrease of the tumor load in the
blood of PS/2-treated mice was also observed (Fig. 2biii);
furthermore, tumor burden in the BM of PS/2-treated mice
was significantly decreased (Fig. 2biv). Further investiga-
tions are needed to determine whether the redistribution by
CD49d inhibition might overcome drug resistance or
improve the effectiveness of other therapeutic agents by
detaching CLL cells from VCAM-1-expressing stromal cells.
Based on our findings, we propose that TCL1-tg mice
represent an adequate model for CD49d-high CLL patients,
and provide evidence that BCR-induced VLA-4 inside-out
activation remains functional upon treatment with ibrutinib,
being in turn hampered upon exposure to idelalisib. This
indicates that PI3K, rather than BTK, is an essential part of
the signaling between the BCR and VLA-4 in the TCL1-tg
model, in part confirming the observation made in humans
[4]. Furthermore, we specified the role of CD49d in disease
Fig. 2 Inhibition of CD49d in mice transplanted with TCL1-tg
splenocytes prevents the engraftment of leukemic cells short-term
in the spleen and long-term in the spleen and bone marrow. a
Wild-type C57BL/6J mice were transplanted intravenously with ~5 Mio
splenocytes from a TCL1-tg mouse, then treated with vehicle (0.9%
NaCl, 1% HP-β-CD) (N= 10, bone marrow N= 9) or the small mole-
cule inhibitor firategrast (N= 12), 30mg/kg/day in drinking water,
starting two (light gray) or seven (dark gray) days post transplantation.
Tumor development was monitored by measuring CD5 and CD19 from
blood samples from the tail vein twice a week. Mice were sacrificed
21 days after transplantation. Organ infiltration and tumor burden were
measured by cell counting (EVE automatic counter) and flow cytometry,
with CD5/CD19 staining identifying leukemic cells. b Wild-type
C57BL/6J mice were transplanted intraperitoneally with 25 Mio CLL
cells from a TCL1-tg mouse, then treated with the CD49d-blocking
antibody PS/2 (N= 10), 10mg/kg, or isotype control (N= 10), injected
intraperitoneally twice a week, starting 7 days post transplantation. Mice
were sacrificed 5 weeks after treatment start (6 weeks post transplanta-
tion). Tumor burden was determined by CD5/CD19 staining and manual
cell counting. The absolute numbers of malignant cells from the (Ai, Bi)
whole spleen, along with its (Aii, Bii) weight, from (Aiii, Biii) blood
(normalized to μl) and from the (Aiv, Biv) bone marrow (extrapolated
from the femora to the whole bone marrow as described in Supple-
mentary Methods) were determined. Unpaired t tests were performed
by GraphPad Prism5. Error bars represent standard deviation (SD).
*P < 0.05; **P < 0.01; ***P < 0.001, ns nonsignificant.
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development by directly targeting this integrin in vivo, which
led to a redistribution of TCL1-tg cells transplanted into WT
mice. From a clinical perspective, we suggest that VLA-4
inhibition or additional targeting of BCR pathway molecules,
e.g., by PI3K inhibitors other than idelalisib to avoid its
severe side effects [15] and potentially targeting different
isoforms, can be promising additions to ibrutinib therapy for
high-risk CD49d-high CLL patients. This could help to
overcome residual BCR-mediated signaling bypassing BTK
and mediating tissue retention facilitated by VLA-4.
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